TY - JOUR
T1 - Age-related patterns of microbial dysbiosis in multiplex inflammatory bowel disease families
AU - Jacobs, Jonathan P.
AU - Spencer, Elizabeth A.
AU - Helmus, Drew S.
AU - Yang, Julianne C.
AU - Lagishetty, Venu
AU - Bongers, Gerold
AU - Britton, Graham
AU - Gettler, Kyle
AU - Reyes-Mercedes, Pamela
AU - Hu, Jianzhong
AU - Hart, Amy
AU - Lamousé-Smith, Esi
AU - Wehkamp, Jan
AU - Landers, Carol
AU - Debbas, Philip
AU - Torres, Joana
AU - Colombel, Jean Frederic
AU - Cho, Judy
AU - Peter, Inga
AU - Faith, Jeremiah
AU - Braun, Jonathan
AU - Dubinsky, Marla
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2024.
PY - 2024/11/11
Y1 - 2024/11/11
N2 - Objective IBD is characterised by dysbiosis, but it remains unclear to what extent dysbiosis develops in unaffected at-risk individuals. To address this, we investigated age-related patterns of faecal and serum markers of dysbiosis in high-risk multiplex IBD families (two or more affected first-degree relatives). Design Faecal and serum samples were collected from multiplex IBD and control families (95 IBD, 292 unaffected, 51 controls). Findings were validated in independent cohorts of 616 and 1173 subjects including patients with IBD, infants born to mothers with IBD and controls. 16S rRNA gene sequencing and global untargeted metabolomics profiling of faeces and serum were performed. results Microbial and metabolomic parameters of dysbiosis progressively decreased from infancy until age 8. This microbial maturation process was slower in infants born to mothers with IBD. After age 15, dysbiosis steadily increased in unaffected relatives throughout adulthood. Dysbiosis was accompanied by marked shifts in the faecal metabolome and, to a lesser extent, the serum metabolome. Faecal and serum metabolomics dysbiosis indices were validated in an independent cohort. Dysbiosis was associated with elevated antimicrobial serologies but not with faecal calprotectin. Dysbiosis metrics differentiated IBD from non-IBD comparably to serologies, with a model combining calprotectin, faecal metabolomics dysbiosis index and serology score demonstrating highest accuracy. Conclusion These findings support that dysbiosis exists as a pre-disease state detectable by faecal and serum biomarkers for IBD risk prediction. Given the expansion of disease-modifying agents and non-invasive imaging, the indices developed here may facilitate earlier diagnoses and improved management in at-risk individuals.
AB - Objective IBD is characterised by dysbiosis, but it remains unclear to what extent dysbiosis develops in unaffected at-risk individuals. To address this, we investigated age-related patterns of faecal and serum markers of dysbiosis in high-risk multiplex IBD families (two or more affected first-degree relatives). Design Faecal and serum samples were collected from multiplex IBD and control families (95 IBD, 292 unaffected, 51 controls). Findings were validated in independent cohorts of 616 and 1173 subjects including patients with IBD, infants born to mothers with IBD and controls. 16S rRNA gene sequencing and global untargeted metabolomics profiling of faeces and serum were performed. results Microbial and metabolomic parameters of dysbiosis progressively decreased from infancy until age 8. This microbial maturation process was slower in infants born to mothers with IBD. After age 15, dysbiosis steadily increased in unaffected relatives throughout adulthood. Dysbiosis was accompanied by marked shifts in the faecal metabolome and, to a lesser extent, the serum metabolome. Faecal and serum metabolomics dysbiosis indices were validated in an independent cohort. Dysbiosis was associated with elevated antimicrobial serologies but not with faecal calprotectin. Dysbiosis metrics differentiated IBD from non-IBD comparably to serologies, with a model combining calprotectin, faecal metabolomics dysbiosis index and serology score demonstrating highest accuracy. Conclusion These findings support that dysbiosis exists as a pre-disease state detectable by faecal and serum biomarkers for IBD risk prediction. Given the expansion of disease-modifying agents and non-invasive imaging, the indices developed here may facilitate earlier diagnoses and improved management in at-risk individuals.
KW - INFLAMMATORY BOWEL DISEASE
KW - INTESTINAL BACTERIA
UR - https://www.scopus.com/pages/publications/85204172616
U2 - 10.1136/gutjnl-2024-332475
DO - 10.1136/gutjnl-2024-332475
M3 - Article
C2 - 39122361
AN - SCOPUS:85204172616
SN - 0017-5749
VL - 73
SP - 1953
EP - 1964
JO - Gut
JF - Gut
IS - 12
ER -